ECG Markers of Hemodynamic Improvement in Patients with Pulmonary Hypertension

Table 1

Baseline characteristics of the study group and a comparison of patients regarding hemodynamic improvement.

	Whole group	No hemodynamic improvement	Hemodynamic improvement
	91	45	46
Age [years]	52.6 ± 16.4	51.3 ± 16.9	53.8 ± 15.9	0.48
Sex (females)	62 (68.1%)	32 (71.1%)	30 (65.2%)	0.55
Etiology
IPAH [, (%)]	54 (59.3%)	27 (60%)	27 (58.7%)	0.9
CTD-APAH [, (%)]	16 (17.6%)	8 (17.8%)	8 (17.4%)	0.96
CHD-APAH [, (%)]	10 (11%)	7 (15.6%)	3 (6.5%)	0.17
Inoperable CTEPH [, (%)]	11 (12.1%)	3 (6.7%)	8 (17.4%)	0.12
6MWD [m]	325.5 ± 105.9	328.3 ± 114.8	322.6 ± 97.3	0.8
NT-proBNP [pg/mL]	2608.3 ± 3139.5	2397.5 ± 2358.9	2824.0 ± 3792	0.52
WHO-FC [mean ± SD]	3.08 ± 0.57	3.0 ± 0.58	3.15 ± 0.55	0.2
RHC:
mRAP [mmHg]	6.8 ± 4.6	6.4 ± 3.8	7.3 ± 5.4	0.39
PAWP [mmHg]	8.1 ± 3.8	8.5 ± 4.0	7.9 ± 3.6	0.47
SpO2 in Ao [%]	91.5 ± 7.3	91.5 ± 7.3	91.6 ± 7.5	0.94
SpO2 in PA [%]	59.7 ± 10.7	59.7 ± 11.7	58.7 ± 9.9	0.99
CI [l/min/m^2]	1.97 ± 0.59	1.97 ± 0.63	1.97 ± 0.55	0.98
PVR [WU]	14.4 ± 8.3	15.7 ± 9.2	13.2 ± 7.1	0.15
Time between consecutive RHC procedures	12.6 ± 10.0	11.3 ± 8.2	13.9 ± 11.4	0.23

Abbreviations. IPAH: idiopathic pulmonary arterial hypertension; CTD-APAH: pulmonary arterial hypertension associated with connective tissue disease; CHD-APAH: pulmonary arterial hypertension associated with congenital heart disease; CTEPH: chronic thromboembolic pulmonary hypertension; 6MWD: 6-minute walking test distance; NT-proBNP: N-terminal pro-B type natriuretic peptide level; WHO-FC: World Health Organization functional class; RHC: right heart catheterization; mRAP: mean right atrial pressure; PAWP: pulmonary artery wedge pressure; SpO₂: oxygen saturation; Ao: aorta; PA: pulmonary artery; CI: cardiac index; PVR: pulmonary vascular resistance.